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RESEARCH ARTICLE Open Access
Comparatively low attendance during Human
Papillomavirus catch-up vaccination among
teenage girls in the Netherlands: Insights from a
behavioral survey among parents
Giedre Gefenaite1,2*†, Marieke Smit1,7†, Hans W Nijman3, Adriana Tami4, Ingrid H Drijfhout5, Astrid Pascal3,
Maarten J Postma1, Bert A Wolters6, Johannes J M van Delden7, Jan C Wilschut4 and Eelko Hak1,2
Abstract
Background: The Dutch Human Papillomavirus (HPV) catch-up vaccination program in 2009 appeared less
successful than expected. We aimed to identify the most important determinants of refusing the vaccination.
Methods: Two thousand parents of girls born in 1996 targeted for HPV vaccination received an invitation letter to
participate in a questionnaire study. Two study groups were defined: the first group consisted of parents of girls
who had accepted the vaccine and already received the first dose of HPV vaccination. The second group consisted
of parents whose daughters were not vaccinated. The questionnaire consisted of a broad spectrum of possible
determinants that were revealed after literature search and discussions with the stakeholders.
Results: Four hundred sixty nine questionnaires (24%) were returned, 307 (31%) from those who accepted and 162
(16%) from those who declined the vaccine. The decision not to accept the vaccine was largely determined by: (i)
perception that the information provided by the government about the vaccine was limited or biased (OR 13.27);
(ii) limited trust, that the government would stop the vaccination program if there were serious side effects (OR
9.95); (iii) lack of knowledge about the effectiveness of the vaccine (OR 7.67); (iv) concerns about the side effects of
the vaccine (OR 4.94); (v) lack of conviction that HPV can be extremely harmful (OR 3.78); (vi) perception that the
government is strongly influenced by vaccine producers (OR 3.54); and (vii) religious convictions (OR 2.18).
Conclusions: This study revealed several determinants for HPV vaccination uptake after implementation of the HPV
vaccine for adolescent girls. These determinants should be taken into consideration in order to successfully
implement HPV vaccination into National Immunization Programs.
Background
Based on the recommendations by the Dutch Health
Council (DHC) in March 2008 [1], the Dutch government
approved implementation of the Human Papillomavirus
(HPV) vaccination as part of the National Immunization
Program (NIP). The vaccine to be used was Cervarix™
(GlaxoSmithKline), which is a bivalent vaccine against
HPV16 and HPV18, and consists of three doses adminis-
tered at baseline, one and six months [2]. The vaccine was
mainly targeted at 12-year-old girls (1997 birth cohort) and
a catch-up vaccination program was planned for 13- to16-
year-old girls (1993–1996 birth cohort) [1]. The catch-up
vaccination campaign started in March 2009, and the regu-
lar vaccination campaign began in 2010. For all targeted
girls the vaccination campaign was free of charge. The girls
received a personal invitation letter with an information
leaflet and were invited to visit local vaccination sessions
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[3]. Although no permission of the parents was required,
the girls were advised to discuss the information and their
decision regarding HPV vaccination with parents or other
family members [4].
Ultimately, slightly above fifty percent (52.3%) of the
targeted catch-up cohort received the HPV vaccine [5].
The vaccination rates varied by age, from 49.0% in 1993
birth cohort to 54.2% in, 1996 birth cohort [5]. By February
2011, similar vaccination rates (52.5%) were observed in the
1997 birth cohort [5]. One suggested reason for such a low
HPV vaccination uptake, as compared to the normal
attendance rates for the regular vaccinations of the NIP of
90% [5], was critical reporting in the media, which accused
the government of emphasizing the advantages rather than
the potential disadvantages of the vaccine. Other reasons,
such as the relative novelty of the vaccine, the fact that it
was the first vaccine for a sexually transmitted infection
and the first vaccine for girls only, and its unknown effec-
tiveness in preventing cancer could have engendered dis-
trust in the parents as well. Another possible factor in
declining HPV vaccination or vaccinations in general, could
be religious beliefs. In the Netherlands, the overall vacci-
nation coverage is much lower in the so-called Bible-belt
region where relatively many people decline vaccinations
because of their religious convictions (http://www.rivm.nl/
en/infectious-diseases/topics/nip/).
Several Dutch studies have already assessed the know-
ledge about and the willingness to receive the HPV vaccine.
These studies have shown that 56%–88% of the respon-
dents would be willing to receive or have their daughter re-
ceive the HPV vaccine [6,7]. Several studies from other
countries that assessed parental attitudes towards HPV
vaccination showed similar rates of intention to vaccinate
(70–80%) [8-10]. Since actual behavior may be different
from intentions, we designed a study which aimed to
assess a broad range of demographic, behavioral, and
organizational determinants, and knowledge and concerns
that were influential in parents’ decision to either accept
or decline the vaccination for their daughters during the
HPV vaccination campaign. Although in the catch-up vac-
cination campaign 13- to 16-years-old girls were invited to
receive HPV vaccinations, only the girls of 13 years of age
were invited to our study as with regard to age their parents
resembled the parents of the 12-years-old girls the best.
Methods
In July 2009, four months after the HPV vaccination
catch-up program for 13- to 16-year-old girls was
initiated, we randomly selected parents of girls born in
1996 who had received a call for the HPV vaccine in the
Northern provinces of the Netherlands. Two study
groups were defined. The first group consisted of parents
of girls who had accepted the vaccine and already received
the first dose of HPV vaccination. The second group
consisted of vaccine decliners. The two groups, including
1000 parents each, were randomly sampled from the
vaccination register. On behalf of the researchers, the
Institute for Public Health and the Environment (RIVM)
sent 2000 invitations to eligible parents to ask if they
would be willing to participate in the study. Parents who
agreed to enroll in the study returned the response cards
with a positive reply and parents who were willing to
participate received a paper questionnaire in Dutch (the
English version added in Additional file 1). After three
weeks a reminder to fill out the questionnaire was sent.
The study was conducted in accordance with the
Dutch Law for the Protection of Personal Data (Wet
Bescherming Persoonsgegevens) and the Declaration of
Helsinki (http://www.wma.net/e/policy/b3.htm). No
medical ethical committee approval was required.
We used an anonymous, self-administered questionnaire
to identify the determinants for not accepting the HPV vac-
cination. In a stakeholders meeting with professionals
involved in the HPV campaign, (a gynecologic oncologist, a
sexologist, a doctor of the Municipal Health Service, a re-
gional manager of coordination programs at the center for
infectious disease control, an epidemiologist, and municipal
health advisors), possible determinants for the uptake of
the HPV vaccination were explored. In addition, a review of
the literature, a stakeholder analysis, and questionnaires
previously developed by our and other research groups [9]
were used to construct a new questionnaire. The parents
were asked to fill out the questionnaire (in Dutch) on behalf
of their daughter who had received a call for the HPV
vaccination. Parents could also express their attitudes to-
wards HPV vaccination in a free text.
The demographical determinants of the parents
included gender, age, marital status, educational level
(none, primary, prevocational, secondary, pre-university,
higher-professional, university), religion (Catholic, Protes-
tant, Islam or other) and country of birth. We also
assessed the participation in a cervical screening program.
We asked whether a participant knew someone with an
abnormal cervical smear or cervical cancer in his/her fa-
mily or circle of acquaintances. Items reflecting behavioral
determinants were based on health behavior criteria
according to the “Health Belief Model” and “Behavioral
Intention Model” [11,12]. We formulated questions based
on five of the six domains in the Health Belief Model; per-
ceived susceptibility, perceived severity, perceived benefits,
perceived barriers and cues to action. We posed questions
on two more domains that exist in the Behavioral
Intention Model; attitudes and social influences. We also
posed questions about parents’ knowledge concerning
HPV and cervical cancer, information services and sources
that influenced decision-making, trust in the government,
vaccination concerns, age-related items, financial issues,
intention to accept the vaccination later, involvement of
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their daughter in the final decision and future acceptance
of other vaccines.
We dichotomized the following variables: education (high
(university, higher professional)/other), being religious (yes/
no), country of birth (the Netherlands/other), knowing
someone with an abnormal cervical smear or cervical
cancer in his/her family or circle of acquaintances (yes/no),
and participation in cervical screening program (yes/no).
The variables assessed with the four- and five-point Likert
scale were dichotomized according to the degree of agree-
ment with the proposition, (4–5 [agree - strongly agree])
for the indicator group, and (1–3 [strongly disagree, dis-
agree and disagree nor agree]) for the reference group.
Knowledge about HPV and HPV vaccination was
assessed by using 10 statements (true/false/does not know),
see Appendix 1. The mean knowledge score was calculated.
The primary outcome was the uptake of the first dose
of the HPV vaccine obtained from RIVM.
All determinants with a p-value lower or equal to 0.10
in the univariate analyses were used in the multivariate
analysis. We used all determinants with a p-value of 0.05
or lower to construct a final logistic regression model.
We calculated odds ratios (OR) and 95% confidence
intervals (95% CI) as measures of associations. The area
under the curve (AUC) for the receiver operating characte-
ristic (ROC) with its 95% CI was calculated. The statistical
analysis was performed using SPSS for Windows (version
16.0; SPSS, Inc Chicago Illinois).
Results
Of the 2000 parents approached by the administrative
offices of the RIVM, 863 parents responded and 609 pa-
rents were willing to co-operate. Four hundred sixty
nine parents returned the questionnaire. Overall the re-
sponse rate was 24% (469/2000), 31% (307) in the group
who received the vaccine versus 16% (162) in the group
who did not. Of the respondents 93% (435/468) were fe-
male, and mean age was 44 years (range 35–55 years). The
mean score for knowledge about HPV and cervical cancer
was 5.65/10 correct answers, 5.54 and 5.88 (p= .09) in those
accepting and refusing the vaccine respectively.
The HPV vaccine was accepted by 66% of the respon-
dents’ daughters while 34% (162/469) declined it. The
majority (96%) of the girls received the second dose.
When the parents could express their attitudes
towards the HPV vaccination, no new determinants of
refusing the vaccine were encountered.
Determinants associated with not accepting the
HPV vaccination
The results from the univariate analysis to determine the
association between the demographic determinants and
not accepting the HPV vaccine are shown in Table 1.
Being religious was a strong demographic determinant
for declining HPV vaccination.
Several behavioral determinants were associated with
declining the HPV vaccination (Table 2). These included
the conviction of the parents that their daughter would
not get infected with HPV, lack of belief that HPV can
be extremely harmful, judgment that it would be un-
likely that their daughter might get cervical cancer in
the future, perception that vaccinations are not effective
in preventing disease, and conviction that HPV is not
sufficiently serious to warrant vaccination.
Many determinants regarding the knowledge, and con-
cerns about the safety of the vaccine and organizational
issues related to government and information services were
associated with declining HPV vaccination (Table 3).
The results from the multivariate analyses indicate that
the strongest determinants of not accepting HPV vacci-
nation were: limited information about the vaccine pro-
vided by the government, limited trust that the government
would stop vaccinations if there were serious side effects
and concerns related to vaccine safety, effectiveness and re-
ligion (Table 4). The AUC for the final model, including all
7 determinants, was 0.96 (95% CI 0.94–0.97).
Discussion
In our study we aimed to identify the determinants
among parents associated with refusal of HPV vacci-
nation for their daughters. We found that, according to
reports of parents, limited information provided by the
government was the strongest predictor for declining
the HPV vaccinations. Although the HPV vaccination
campaign included the distribution of invitation letters to
families with daughters in the target group and recruitment
was supported by a nationwide information campaign tar-
geting health care professionals and the general public [13],
these efforts were not sufficient to persuade people to
accept the vaccine. Possible explanation, as mentioned be-
fore, could include critical media reports that accused the
government of emphasizing the advantages rather than the
disadvantages of the vaccine. However, it has also been
shown that the content of media reports sometimes may
lack important information related to the vaccination or
the disease [14] which could be misleading.
Another strong determinant for declining the HPV vac-
cination was a lack of trust that the government would stop
vaccination if there were serious side effects. This concern
might partly be a consequence of reports about potential
associations between certain vaccines and serious adverse
events, such as pandemic influenza vaccine and Guillain-
Barré syndrome [15]. This suggests that providing informa-
tion about the management of vaccine side effects may
improve the trust in the government as well.
Concerns about the HPV vaccine effectiveness and safety
were associated with refusal of the HPV vaccination. One
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Dutch study showed that those who were not willing to
have their children vaccinated said that they would agree to
do so after the vaccine had been used for several years [7].
Secondly, it has also been found that 88% of parents said
they would be willing to have their children vaccinated if
the government approved the vaccine [7]. Although the
HPV vaccine was approved by the Dutch government,
which means that a list of criteria such as acceptable safety
and effectiveness profiles had to be met [16], the actual be-
havior was not consistent with parents’ reported intentions.
Only slightly above 50% of the target population accepted
the HPV vaccine. Differences between the intentions and
the actual behavior regarding the uptake of the HPV vacci-
nations may therefore be of interest for future research.
Our findings indicate that parents of vaccinated and
unvaccinated girls hold very different views on the seve-
rity of HPV infection and the likelihood that their
daughters might acquire an HPV infection or cervical
cancer and on the question as to whether the informa-
tion about HPV vaccination was adequate. Parents
whose daughters were not vaccinated perceived less risk
associated with HPV and cervical cancer. Interestingly
they felt, more often, that information about HPV
vaccination was not sufficient to make a good decision.
Although the entire target group received the same
information about the HPV vaccination, these findings
suggest that the attitudes towards HPV vaccination were
largely influenced by more subjective reasons.
The results of our study show that religious respondents
were less likely to accept the vaccine. Another Dutch study
also found that voters for religious parties are less likely to
accept HPV vaccination [3]. This observation is consistent
with the general refusal of childhood vaccination by a




The findings from other countries however provide only
limited evidence about the association between religion
and HPV vaccine uptake [10, 9].
Moreover, preliminary results from other countries
show that HPV vaccination coverage largely depends on
the type of vaccination program that is implemented. A
school-based approach was superior to vaccination pro-
grams on-demand through health professionals, the lat-
ter being implemented in the Netherlands [13]. The
three-dose vaccination coverage in Scotland in the 1996
birth cohort via a school-based HPV vaccination cam-
paign was 86% [17]. It therefore appears that apart from
a need for clearer and more transparent messages to the








It’s not likely that my daughter gets infected with HPV some day 81/306 (26.5%) 59/162 (36.4%) 1.59 (1.06–2.39) 0.03
I don’t believe HPV can be extremely harmful 37/304 (12.2%) 39/162 (24.1%) 2.29 (1.39–3.77) 0.001
It’s not possible that my daughter gets infected with HPV some day 27/305 (8.9%) 13/160 (8.1%) 0.91 (0.46–1.82) 0.79
I don’t believe HPV can cause cervical cancer 24/305 (7.9%) 7/161 (4.3%) 0.53 (0.22–1.26) 0.15
It’s not possible that my daughter gets cervical cancer in the future 15/306 (4.9%) 3/162 (1.9%) 0.37 (0.10–1.28) 0.10
I don’t believe that cervical cancer is a serious disease 4/305 (1.3%) 1/162 (0.6%) 0.47 (0.05–4.22) 0.49
It’s not likely that my daughter gets cervical cancer in the future 80/306 (26.1%) 62/160 (38.8%) 1.79 (1.19–2.69) 0.01
Cervical cancer is not something I’m worried about right now for my
daughter
117/305 (38.4%) 60/162 (37%) 0.95 (0.64–1.40) 0.78
Vaccines aren’t effective in preventing diseases 12/303 (4.0%) 25/153 (16.3%) 4.74 (2.31–9.72) <0.001
HPV is not that serious to get vaccinated for 6/302 (2%) 24/155 (15.5%) 9.04 (3.61–22.63) <0.001








Educational level, high 74/305 (24.3%) 51/162 (31.5%) 1.43 (0.94–2.19) 0.09
Religious, yes 152/306 (49.7%) 113/162 (69.8%) 2.34 (1.56–3.50) <0.001
Country of birth, the Netherlands 298/306 (97.4%) 158/162 (97.5%) 1.06 (0.31–3.58) 0.93
Knowing someone with an abnormal cervical smear or cervical cancer
in his/her family or acquaintances, no
181/306 (59.2%) 83/162 (51.2%) 0.73 (0.50–1.06) 0.10
Participation in cervical screening, no 23/306 (7.5%) 10/162 (6.2%) 0.81 (0.37–1.75) 0.59
Regular NIP vaccinations, no 0/304 (0%) 21/162 (13%) .32 (.28–.36) <0.001
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public, different approaches to reach the target popula-
tion should also be considered.
From the discussions with the stakeholders at the be-
ginning of our study and during the start of the HPV
vaccination campaign in the Netherlands it appeared
that parents have much influence on the decision as to
whether or not to vaccinate their daughters. However,
vaccination coverage rates may also be influenced by the








I’m very worried about the side effects of the HPV vaccination 79/301 (26.2%) 140/160 (87.5%) 19.67 (11.53–33.56) <0.001
We know way too little about the effects of the vaccine 172/298 (57.7%) 158/161 (98.1%) 38.58 (12.03–123.71) <0.001
We don’t know a lot about the side effects of the vaccine 179/298 (60.1%) 155/161 (96.3%) 17.17 (7.36–40.09) <0.001
It’s not very important that my children receive all their vaccinations 10/305 (3.3%) 51/156 (32.7%) 14.33 (7.02–29.25) <0.001
I won’t do everything to prevent my daughter getting cervical cancer 7/306 (2.3%) 9/159 (5.7%) 2.56 (0.94–7.02) 0.06
There are already too many vaccines in the Dutch vaccination
program
14/306 (4.6%) 26/160 (16.3%) 4.05 (2.05–8.00) <0.001
I would had have more information to make a good decision 143/305 (46.9%) 136/160 (85.0%) 6.42 (3.94–10.47) <0.001
I feel I didn’t get enough information to make a good decision 93/303 (30.7%) 95/161 (59%) 3.25 (2.18–4.84) <0.001
I think the information about the vaccine provided by the
government was very limited/biased
115/301 (38.2%) 150/154 (97.4%) 60.65 (21.88–168.17) <0.001
I think the information about the vaccine provided by the
government was not very clear
119/304 (39.1%) 138/160 (86.3%) 9.75 (5.88–16.17) <0.001
I don’t believe/trust that the government would stop vaccinations if
there was evidence of serious side effects
14/305 (4.6%) 87/156 (55.8%) 26.21 (14.06–48.84) <0.001
The government is strongly influenced by the vaccine producers 49/284 (17.3%) 126/153 (82.4%) 22.38 (13.34–37.54) <0.001
There weren’t enough locations to get the vaccination 9/306 (2.9%) 6/158 (3.8%) 1.30 (0.46–3.73) 0.62
It wasn’t very clear when my daughter could get the HPV vaccine 12/306 (3.9%) 6/158 (3.8%) 0.97 (0.36–2.63) 0.95
Doctors do not take parents seriously regarding the side effects of
vaccinations
35/295 (11.9%) 64/155 (41.3%) 5.22 (3.25–8.41) <0.001
I think it’s good that the HPV vaccine exists, but not at this age 31/303 (10.2%) 79/152 (52.0%) 9.50 (5.82–15.49) <0.001
I don’t think my daughter is very capable to make her own decision
about accepting the vaccination
208/302 (68.9%) 112/158 (70.9%) 1.10 (0.72–1.68) 0.66
I would get my daughter vaccinated if the vaccine wasn’t only for girls
but also for boys
141/303 (46.5%) 12/155 (7.7%) 0.10 (0.05–0.18) <0.001
Girls who had the HPV vaccination would be more likely to have
unprotected sex
5/306 (1.6%) 19/155 (12.3%) 8.38 (3.07–22.92) <0.001
Having the HPV vaccination might make girls more likely to have sex 21/305 (6.9%) 34/161 (21.1%) 3.62 (2.02–6.49) <0.001
I would strongly disapprove if my daughter would be sexually active
at this age
290/305 (95.1%) 151/162 (93.2%) 0.71 (0.32–1.58) 0.40
Other girls might be vaccinated, but my daughter won’t 7/306 (2.3%) 12/157 (7.6%) 3.54 (1.36–9.17) 0.01





OR (95% CI) p-value
I think theinformation about the vaccine provided by the
government was very limited
103/273(37.3%) 141/145(97.2%) 13.74 (3.82–49.46) <0.001
I have no trust that the government would stop the vaccinations if
there was evidence of serious side effects
13/273(4.8%) 81/145(55.9%) 10.13 (4.06–25.60) <0.001
We know way too little about the effects of the vaccine 153/273(56%) 143/145(98.6%) 8.34 (1.41–49.50) 0.02
I’m very worried about the side effects of the HPV vaccination 69/273(25.3%) 127/145(87.6%) 4.71 (2.13–10.44) <0.001
I don’t believe HPV can be extremely harmful 34/273(12.5%) 38/145(26.2%) 4.19 (1.63–10.82) 0.03
The government is strongly influenced by the vaccine producers 47/273(17.2%) 120/145(82.8%) 3.60 (1.74–7.47) 0.001
Religious conviction 133/273 (48.7%) 101/145 (69.7%) 2.17 (1.09–4.40) 0.03
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girls’ opinions themselves. It has been shown that differ-
ent information sources may be preferred by girls of
different age [18,19]. For example, information pro-
vided by health care professionals and mass media
(television, the internet) seemed to be a preferred
source of information among older teenage girls (15-
to 18- or 19-years-old) while younger teenagers (11-
or 12- to 14-years-old) had more trust in schools,
teachers and family [18,19]. Guidance about HPV
and HPV vaccination could therefore be provided
through the preferred sources of information for
different age groups.
Some limitations of the study need to be addressed.
The overall response rate was not high (24%). One of
the possible explanations is the two-step response
process we employed in which parents were first asked
to return a card for participation and only then received
a questionnaire. Importantly, the response rate was twice
as high among those who received the vaccine versus
those who did not (31% versus 16%). This might have
introduced bias because those with more positive atti-
tudes towards vaccination were better represented in
our study. We expect that the bias introduced more
contrast between positive and negative attitudes than in
the general population, which agrees with the exception-
ally high discriminative value of the predictive model
(AUC-value of 0.96). This means that in the general
population the role of these determinants is likely to be
less important than what we observed in our study. On
the other hand, given the fact that some baseline charac-
teristics were comparable to the general Dutch popula-
tion the sample seemed to mirror the source population
of the Netherlands. Our study also assessed a broad
spectrum of possible determinants associated with de-
clining HPV vaccination.
The incidence and mortality from cervical cancer in
the Netherlands is one of the lowest in Europe. However,
since it is the second most common cancer in 18- to 44-
years-old women [20], efforts should be made to prevent
it. If 70% of the cervical cancers can be prevented by the
currently registered HPV vaccines, it could largely re-
duce physical and psychological disease burden for the
females and their families.
Conclusions
We identified several determinants for the low HPV vac-
cination uptake. Modifying these determinants might be
essential during planning, implementation and continu-
ation of the HPV vaccination programs inside and
outside the Netherlands. Furthermore, openness and dis-
cussion about the pros and cons of HPV vaccination as
well as the use of a variety of communication strategies
may be helpful for a more successful implementation of
HPV vaccination programs.
Appendix 1. Knowledge about HPV infection
1. Often HPV does not present with visible symptoms
(true).
2. A cervical smear induces cervical HPV infection
(false).
3. HPV usually disappears without treatment (true).
4. More sexual partners increase the risk to get HPV
infection (true).
5. It is possible to have HPV for a long time without
knowing (true).
6. HPV can be transmitted during the sexual contact
(true).
7. HPV can cause the cervical cancer (true).
8. Most of the sexually active people at some point get
HPV (true).
9. A condom provides 100% protection against HPV
(false).
10.If you have HPV, you always know it (false).
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